The following summarizes some of the highlights from the 11th Congress of the European Academy of Neurology, Helsinki, Finland, June 21-24, 2025.
sNfL as a biomarker of treatment response
MS risk allele associated with retinal layer thinning
Novel uses proposed for Ozempic
Analysing broad-rimmed lesions in MS
Detection and diagnosis
Treatment initiation
Untreated patients
Most Canadian patients with multiple sclerosis learn they may have MS from their family doctor or other healthcare professional rather than a neurologist, according to the results of a recent survey. From February to May 2025, Lind Publishing conducted twin surveys of MS healthcare professionals on NeuroSens and of MS patients on its sister website MSology (www.msology.com). There were 64 responses to the HCP survey and 66 responses to the patient survey. Read More
Part 1
A majority of patients with multiple sclerosis in Canada are advised to start treatment with a disease-modifying therapy, most commonly with an anti-CD20 treatment, according to the results of a recent survey on NeuroSens. The survey was conducted from 27 February-31 March 2025 and received 64 responses from MS neurologists and nurses. Read More
Webinar on recent adjunctive antiseizure medications with an emphasis on the use of cenobamate for focal epilepsies and fenfluramine for Dravet syndrome. Read More